Analysts Set Atyr PHARMA INC (NASDAQ:ATYR) Target Price at $19.25

Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received an average rating of "Buy" from the seven research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $18.60.

A number of brokerages have weighed in on ATYR. Leerink Partners started coverage on Atyr PHARMA in a research note on Tuesday. They issued an "outperform" rating and a $16.00 target price on the stock. Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating for the company. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a report on Tuesday, December 10th.

Atyr PHARMA Trading Down 2.5 %

Shares of ATYR stock traded down $0.11 during trading hours on Tuesday, hitting $4.32. 1,767,908 shares of the company's stock traded hands, compared to its average volume of 987,059. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a market cap of $362.62 million, a PE ratio of -4.60 and a beta of 1.10. The stock's 50 day simple moving average is $3.61 and its 200 day simple moving average is $2.87. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Group One Trading LLC bought a new position in shares of Atyr PHARMA in the fourth quarter worth about $26,000. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA during the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA during the 4th quarter worth $39,000. Finally, JPMorgan Chase & Co. grew its position in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock worth $55,000 after buying an additional 10,754 shares in the last quarter. Institutional investors own 61.72% of the company's stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.